AMONETA DIAGNOSTICS

Amoneta offers a unique diagnostic test for an unmet, high medical need: Reliable early diagnosis of Alzheimer's Disease.

The test is performed on a minimal blood sample, based on the detection of two complementary biomarkers. The first results show a reliability up to 95% in human subjects, even 100% in animals. The competitive advantages of ADDIA test are (1) the ease of implementation, rapid, minimally invasive, effective laboratory routine and inexpensive, (2) reliability, compared to all existing competitor tests (3) repeatability, the fact that it can be repeated without bias, unlike neuropsychological tests.

Compared to competitor companies developing blood biomarkers, Amoneta is ahead as it is the only company so far with clinical development on 1024 patients being recruited in its late stage clinical studies.